Core Viewpoint - The company, Hongbo Pharmaceutical, has experienced significant stock price fluctuations since January 8, 2026, with a cumulative increase surpassing most peers in the industry and significantly exceeding the growth of relevant indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] Group 1 - The company's stock price has shown a substantial increase, leading to a higher profit adjustment risk due to accumulated gains [1] - A self-examination was conducted by the company, and a letter was sent to the controlling shareholder and actual controller for verification, confirming no undisclosed significant matters related to the company as of the announcement date [1] - The company's operations are currently normal, with no significant changes reported [1] Group 2 - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall operating income, indicating it does not significantly impact the overall business performance [1]
泓博医药：DiOrion平台药物研发服务的直接收入占公司整体营业收入的比重较小